Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODSH with ICE Chemotherapy in Pediatric Solid Tumors
NCT02164097Phase 1Terminated
- Sponsor
- New York Medical College
- Start
- Jan 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dociparstat sodium in chemotherapy-induced thrombocytopenia (CIT), sponsored by New York Medical College. Primary endpoint: Safety and Tolerability of ODSH at 60 days. Started Jan 2015; status: terminated.
02
Drugs
dociparstat sodium
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT02164097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164097.